


(R)-(+)-Atenolol

Cat. No.:	HY-B2111		
CAS No.:	56715-13-0		
Molecular Formula:	C ₁₄ H ₂₂ N ₂ O ₃		
Molecular Weight:	266.34		
Target:	Adrenergic Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (375.46 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.7546 mL	18.7730 mL	37.5460 mL
	5 mM	0.7509 mL	3.7546 mL	7.5092 mL
	10 mM	0.3755 mL	1.8773 mL	3.7546 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(R)-(+)-Atenolol is the less active enantiomer of the (R,S)-atenolol. (R,S)-atenolol is a β-adrenergic receptor antagonist^{[1][2]}.

IC₅₀ & Target

β adrenergic receptor

REFERENCES

[1]. Batra S, et al. Bioassay, determination and separation of enantiomers of atenolol by direct and indirect approaches using liquid chromatography: A review. Biomed Chromatogr. 2018 Jan;32(1).

[2]. Stoschitzky K, et al. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality. 1993;5(1):15-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA